Immunohistochemical PD-L1 expression analysis has been shown to be a predictive biomarker for ICB treatment outcomes in numerous tumor entities and, in this regard, is already routinely being considered for treatment decisions in entities such as NSCLC and urogenitary cancers (12). The gene discussed is CD274; the disease is non-small cell lung carcinoma.